Loading company…
ViceBio develops vaccines for viral respiratory diseases using its Molecular Clamp technology.
Founded in 2019 and based in London, UK, ViceBio develops vaccines for viral respiratory diseases, including RSV and hMPV. Its Molecular Clamp technology is designed to support broad protection and manufacturable formulations. In July 2025, Sanofi agreed to acquire the company for USD 1.15 billion plus up to USD 450 million in development and regulatory milestone payments, subject to closing conditions and regulatory approvals.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in